

Financial highlights

Seen over a 5-year period, the development of the Company may be described by means of the following financial highlights:

	Group				
	<u>2020</u>	<u>2019</u>	<u>2018</u>	<u>2017</u>	<u>2016</u>
	MDKK	MDKK	MDKK	MDKK	MDKK
Key figures					
Revenue	29	36	17	16	16
Profit/loss before amortisation/depreciation and impairment losses	-31	-14	-37	32	-40
Profit/loss before net financials	-12	-74	-46	8	-89
Net financials	32	244	-127	20	114
Profit from discontinued activities	0	0	0	1.377	106
Profit/loss for the year	21	128	-143	1.388	130
Balance sheet					
Balance sheet total	3.489	3.581	3.434	3.462	2.862
Investment in property, plant and equipment	-70	-203	-186	-167	-263
	2.903	2.793	2.921	3.066	1.680
Cash flows from:					
- operating activities	9	-66	-42	1.318	190
- investing activities	321	137	-128	-1.111	-195
- financing activities	-405	13	159	74	-142
The year's changes in cash and cash equivalents	-76	84	-11	281	-146
Number of employees	26	27	26	19	18
Financial ratios					
Solvency ratio	83,2%	78,0%	85,1%	88,6%	58,7%
Return on equity	0,7%	4,5%	-4,8%	58,5%	7,8%

Without adjusting comparative figures, the accounting policies for investment properties from and including 2020 have been changed so that investment properties are recognized at fair value.

For all years cash flow including discontinued activities.

The subsidiary Fertin Pharma A/S was divested in 2017, which is why the result of discontinued activities after tax for 2017 and 2016 is shown in a separate line.